Intellia Therapeutics to present updated data from Phase 1/2 study of NTLA-2002

Intellia Therapeutics announced the acceptance of an oral presentation from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study at the European Academy of Allergy and Clinical Immunology, EAACI, Congress 2024, taking place May 31 – June 3 in Valencia, Spain. NTLA-2002 is an investigational in vivo CRISPR-based gene editing therapy in development as a single-dose treatment for hereditary angioedema, HAE, a rare genetic condition that leads to potentially life-threatening swelling attacks. The presentation will include updated safety and efficacy results from the Phase 1 study across all three dose cohorts.